Pornography Abstinence and Nocturnal Erections in Adult Men
ConditionErection; Incomplete
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorEfforia, Inc
About this trial
The effects of pornography use on male sexual health remain uncertain, with mixed findings across existing literature and substantial variability at the individual level. This observational study is designed to help participants evaluate how a 30-day period of pornography abstinence affects their own sexual health and well-being, with a specific focus on nocturnal penile tumescence as a physiological biomarker.
Participants will complete a short baseline observation period during which they maintain their usual pornography consumption patterns, followed by a 30-day abstinence period. Objective nocturnal erection data will be collected using a connected wearable device, alongside validated self-report questionnaires assessing erectile function, sexual desire, mood, energy, and emotional well-being. Participants serve as their own control, allowing for within-person comparisons of outcomes before and during the abstinence period.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Adult males of legal age of consent
Willingness to attempt pornography abstinence
Ability to use a wearable device during sleep
Ability to complete electronic surveys
Disqualifiers
Have a history of significant sexual dysfunction requiring active medical treatment
Have current or uncontrolled mental health disorders
Have a history of addictive behaviors that may be exacerbated by abstinence
Are undergoing hormonal therapy or treatment affecting sexual function
Trial population
Adult men who are interested in evaluating how a 30-day period of pornography abstinence may affect their sexual health, nocturnal erections, and overall well-being. Participants are self-selected volunteers who report current or recent pornography use, are able to attempt abstinence for the duration of the study, and are willing to use a non-invasive wearable device to collect nocturnal penile tumescence data and complete electronic questionnaires. The study population reflects a real-world, consumer-based sample rather than a clinically diagnosed population.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Pornography Abstinence
BehavioralParticipants will attempt to abstain from all pornography use for 30 consecutive days. Any deviations from abstinence are self-reported and logged for contextual analysis.
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: Single Arm longitudinal where participants act as their own control1 intervention
Trial outcomes
Primary outcomes
1
Change in Nocturnal Penile Tumescence
Measure: Adam Sensor - Nocturnal Erection Tracking Description: Objective measurement of nocturnal penile tumescence, Frequency/Time nocturnal erections per night
Time frame
Baseline Day to Day 38Secondary outcomes
1
Change in Erectile Function
Measure: International Index of Erectile Function (IIEF-15) Scale Range: 5-75 (higher scores indicate better erectile and sexual function) Description: Assesses erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction.
Time frame
Baseline to Day 38 after intervention2
Change in Sexual Desire
Measure: Sexual Desire Inventory-2 (SDI-2) Scale Range: 0-112 (higher scores indicate greater sexual desire) Description: Measures both dyadic and solitary sexual desire.
Time frame
Baseline to Day 38 after intervention3
Change in Pornography Consumption Patterns
Measure: Weekly Pornography Consumption Survey (custom self-report) Scale: Frequency and duration categories (ordinal) Description: Tracks self-reported pornography use and abstinence adherence.
Time frame
Baseline to Day 38 after intervention4
Change in Mood, Energy, and Emotional Well-Being
Measure: Weekly Self-Assessment Check-In (custom) Scale: 1-10 Likert-type scales (higher scores indicate more favorable states) Description: Assesses perceived mood, mental clarity, energy level, and emotional resilience.
Time frame
Baseline to Day 38 after interventionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov